2025 Q3 -tulosraportti
29 päivää sitten1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,79 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 987 094
Myynti
Määrä
1 975 340
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 140 | - | - | ||
| 13 | - | - | ||
| 66 | - | - | ||
| 95 | - | - | ||
| 95 | - | - |
Ylin
308,5VWAP
Alin
303,8VaihtoMäärä
1 301,4 4 265 824
VWAP
Ylin
308,5Alin
303,8VaihtoMäärä
1 301,4 4 265 824
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. | |
| 2025 Q1 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenNovo in dollars has already fallen by approximately 44 percent, while Eli Lilly has risen almost 33 percent. Besides it being a huge difference in how the market values the companies, it also indicates that the market has very great confidence in Eli Lilly and that their products are better. It also indicates that the obesity market is valued very highly, just not Novo. If Novo cannot manage to improve performance by its own efforts, there is also the chance that Eli Lilly will suffer a setback, which can lift Novo. Problems in production will cost Eli Lilly dearly.
·4 t sittenI am still a buyer of Novo Nordisk shares in my extra custody account. I bought from approx. 550 kr. to 272 kr. I am lucky to have a low Average Cost Price on Novo Nordisk shares. So there's nothing to worry about. Or no difficulties. I bought a few more Novo Nordisk today. and lowered my Average Cost Price. A storm in a teacup can seem overwhelming: frightening if you look at it up close. But seen in perspective: With a long-term perspective, it's just another storm: If someone has decided that they can't be bothered anymore: ”and sells their own Novo Nordisk shares” They are lucky that at least I am a buyer of more Novo Nordisk shares. I don't expect big increases today tomorrow next week – month – year: let's say around 400 # But in 2 years' time, we are there, let's say we start at 500 # And now we are in full swing and next year 600#- 700# Etc. My plan is to reduce / rebalance 50% quantity at plus 100% of my Average Cost Price. And keep the rest. Novo Nordisk has been a good teacher for me; I have realized that being able to calculate intrinsic value –is part of the game for me, so as not to get lost in the stock market jungle. In the old days, I had #forgotten# that Novo Nordisk was biotechnology and that it could be dangerous. It was becoming a law of nature that Novo Nordisk could only rise. And when I took profit in my other custody account at approx. 630 kr. and it kept rising, it looked like a misfire. Which now looks like it's better to hit the target than to shoot wide. 15 months, Novo Nordisk has gone from over 1000 kr. to over 300 kr. in price. From overvalued to undervalued. I think we will be at 500 kr.-700 kr. In 1 year - 2 years 3 years. I am long, have time and patience to wait for a good result. We'll see. But that the wearing down is small and the exhausting aspect is greater than big, I have no doubt about.
·6 t sittenNovo might unfortunately be dead for several more years. Momentum strategy is having golden days and bad momentum is followed by even more bad momentum. Be careful not to buy too much. I've said it before. Novo's future is not as bright as it has been. They earn good money, but the time of double-digit growth is over. In the coming years, we will be lucky if Novo provides earnings growth. Much indicates that next year will be with negative growth due to large price regulations, poor Wegovy momentum, and a low dollar. The pill might give a little, but not enough to correct the negative drivers. I own quite a few shares, but I'm definitely not buying more, even though it's tempting. It has been tempting too many times and has been foolish every time 😄
·3 t sittenWhen everyone, even loyal shareholders, are pessimistic and about to give up, one should buy. You are paradoxically a buy signal! :-D
·6 t sittenReminds one of how few of all overweight people receive treatment today - just a few %. One can draw a parallel with Apple 2007. They launched a smartphone that no one knew they needed. Now no one can live without them. Could something similar happen with weight control pills? Will we be popping pills and staring at our phones, or will we put down our phones and start taking forest walks?
·4 t sitten · MuokattuI completely see the same thing playing out and am probably wrong. But I really think that it “spreads” when you see the neighbor lose 20 kg by taking a pill. I also think that the barrier of having to inject oneself disappears with the pill. As far as I can read, the pill is not easy to copy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
29 päivää sitten1 t 9 min
3,75 DKK/osake
Viimeisin osinko
3,79 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNovo in dollars has already fallen by approximately 44 percent, while Eli Lilly has risen almost 33 percent. Besides it being a huge difference in how the market values the companies, it also indicates that the market has very great confidence in Eli Lilly and that their products are better. It also indicates that the obesity market is valued very highly, just not Novo. If Novo cannot manage to improve performance by its own efforts, there is also the chance that Eli Lilly will suffer a setback, which can lift Novo. Problems in production will cost Eli Lilly dearly.
- ·4 t sittenI am still a buyer of Novo Nordisk shares in my extra custody account. I bought from approx. 550 kr. to 272 kr. I am lucky to have a low Average Cost Price on Novo Nordisk shares. So there's nothing to worry about. Or no difficulties. I bought a few more Novo Nordisk today. and lowered my Average Cost Price. A storm in a teacup can seem overwhelming: frightening if you look at it up close. But seen in perspective: With a long-term perspective, it's just another storm: If someone has decided that they can't be bothered anymore: ”and sells their own Novo Nordisk shares” They are lucky that at least I am a buyer of more Novo Nordisk shares. I don't expect big increases today tomorrow next week – month – year: let's say around 400 # But in 2 years' time, we are there, let's say we start at 500 # And now we are in full swing and next year 600#- 700# Etc. My plan is to reduce / rebalance 50% quantity at plus 100% of my Average Cost Price. And keep the rest. Novo Nordisk has been a good teacher for me; I have realized that being able to calculate intrinsic value –is part of the game for me, so as not to get lost in the stock market jungle. In the old days, I had #forgotten# that Novo Nordisk was biotechnology and that it could be dangerous. It was becoming a law of nature that Novo Nordisk could only rise. And when I took profit in my other custody account at approx. 630 kr. and it kept rising, it looked like a misfire. Which now looks like it's better to hit the target than to shoot wide. 15 months, Novo Nordisk has gone from over 1000 kr. to over 300 kr. in price. From overvalued to undervalued. I think we will be at 500 kr.-700 kr. In 1 year - 2 years 3 years. I am long, have time and patience to wait for a good result. We'll see. But that the wearing down is small and the exhausting aspect is greater than big, I have no doubt about.
- ·6 t sittenNovo might unfortunately be dead for several more years. Momentum strategy is having golden days and bad momentum is followed by even more bad momentum. Be careful not to buy too much. I've said it before. Novo's future is not as bright as it has been. They earn good money, but the time of double-digit growth is over. In the coming years, we will be lucky if Novo provides earnings growth. Much indicates that next year will be with negative growth due to large price regulations, poor Wegovy momentum, and a low dollar. The pill might give a little, but not enough to correct the negative drivers. I own quite a few shares, but I'm definitely not buying more, even though it's tempting. It has been tempting too many times and has been foolish every time 😄·3 t sittenWhen everyone, even loyal shareholders, are pessimistic and about to give up, one should buy. You are paradoxically a buy signal! :-D
- ·6 t sittenReminds one of how few of all overweight people receive treatment today - just a few %. One can draw a parallel with Apple 2007. They launched a smartphone that no one knew they needed. Now no one can live without them. Could something similar happen with weight control pills? Will we be popping pills and staring at our phones, or will we put down our phones and start taking forest walks?·4 t sitten · MuokattuI completely see the same thing playing out and am probably wrong. But I really think that it “spreads” when you see the neighbor lose 20 kg by taking a pill. I also think that the barrier of having to inject oneself disappears with the pill. As far as I can read, the pill is not easy to copy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 987 094
Myynti
Määrä
1 975 340
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 140 | - | - | ||
| 13 | - | - | ||
| 66 | - | - | ||
| 95 | - | - | ||
| 95 | - | - |
Ylin
308,5VWAP
Alin
303,8VaihtoMäärä
1 301,4 4 265 824
VWAP
Ylin
308,5Alin
303,8VaihtoMäärä
1 301,4 4 265 824
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. | |
| 2025 Q1 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
29 päivää sitten1 t 9 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11. | |
| 2025 Q3 -tulosraportti | 5.11. | |
| 2025 Q2 -tulosraportti | 7.8. | |
| 2025 Q2 -tulosraportti | 6.8. | |
| 2025 Q1 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
3,75 DKK/osake
Viimeisin osinko
3,79 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenNovo in dollars has already fallen by approximately 44 percent, while Eli Lilly has risen almost 33 percent. Besides it being a huge difference in how the market values the companies, it also indicates that the market has very great confidence in Eli Lilly and that their products are better. It also indicates that the obesity market is valued very highly, just not Novo. If Novo cannot manage to improve performance by its own efforts, there is also the chance that Eli Lilly will suffer a setback, which can lift Novo. Problems in production will cost Eli Lilly dearly.
- ·4 t sittenI am still a buyer of Novo Nordisk shares in my extra custody account. I bought from approx. 550 kr. to 272 kr. I am lucky to have a low Average Cost Price on Novo Nordisk shares. So there's nothing to worry about. Or no difficulties. I bought a few more Novo Nordisk today. and lowered my Average Cost Price. A storm in a teacup can seem overwhelming: frightening if you look at it up close. But seen in perspective: With a long-term perspective, it's just another storm: If someone has decided that they can't be bothered anymore: ”and sells their own Novo Nordisk shares” They are lucky that at least I am a buyer of more Novo Nordisk shares. I don't expect big increases today tomorrow next week – month – year: let's say around 400 # But in 2 years' time, we are there, let's say we start at 500 # And now we are in full swing and next year 600#- 700# Etc. My plan is to reduce / rebalance 50% quantity at plus 100% of my Average Cost Price. And keep the rest. Novo Nordisk has been a good teacher for me; I have realized that being able to calculate intrinsic value –is part of the game for me, so as not to get lost in the stock market jungle. In the old days, I had #forgotten# that Novo Nordisk was biotechnology and that it could be dangerous. It was becoming a law of nature that Novo Nordisk could only rise. And when I took profit in my other custody account at approx. 630 kr. and it kept rising, it looked like a misfire. Which now looks like it's better to hit the target than to shoot wide. 15 months, Novo Nordisk has gone from over 1000 kr. to over 300 kr. in price. From overvalued to undervalued. I think we will be at 500 kr.-700 kr. In 1 year - 2 years 3 years. I am long, have time and patience to wait for a good result. We'll see. But that the wearing down is small and the exhausting aspect is greater than big, I have no doubt about.
- ·6 t sittenNovo might unfortunately be dead for several more years. Momentum strategy is having golden days and bad momentum is followed by even more bad momentum. Be careful not to buy too much. I've said it before. Novo's future is not as bright as it has been. They earn good money, but the time of double-digit growth is over. In the coming years, we will be lucky if Novo provides earnings growth. Much indicates that next year will be with negative growth due to large price regulations, poor Wegovy momentum, and a low dollar. The pill might give a little, but not enough to correct the negative drivers. I own quite a few shares, but I'm definitely not buying more, even though it's tempting. It has been tempting too many times and has been foolish every time 😄·3 t sittenWhen everyone, even loyal shareholders, are pessimistic and about to give up, one should buy. You are paradoxically a buy signal! :-D
- ·6 t sittenReminds one of how few of all overweight people receive treatment today - just a few %. One can draw a parallel with Apple 2007. They launched a smartphone that no one knew they needed. Now no one can live without them. Could something similar happen with weight control pills? Will we be popping pills and staring at our phones, or will we put down our phones and start taking forest walks?·4 t sitten · MuokattuI completely see the same thing playing out and am probably wrong. But I really think that it “spreads” when you see the neighbor lose 20 kg by taking a pill. I also think that the barrier of having to inject oneself disappears with the pill. As far as I can read, the pill is not easy to copy.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 987 094
Myynti
Määrä
1 975 340
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 140 | - | - | ||
| 13 | - | - | ||
| 66 | - | - | ||
| 95 | - | - | ||
| 95 | - | - |
Ylin
308,5VWAP
Alin
303,8VaihtoMäärä
1 301,4 4 265 824
VWAP
Ylin
308,5Alin
303,8VaihtoMäärä
1 301,4 4 265 824
Välittäjätilasto
Dataa ei löytynyt